Discovery of novel antitumor dibenzocyclooctatetraene derivatives and related biphenyls as potent inhibitors of NF-κB signaling pathway. 2014

Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.

Several dibenzocyclooctatetraene derivatives (5-7) and related biphenyls (8-11) were designed, synthesized, and evaluated for inhibition of cancer cell growth and the NF-κB signaling pathway. Compound 5a, a dibenzocyclooctatetraene succinimide, was discovered as a potent inhibitor of the NF-κB signaling pathway with significant antitumor activity against several human tumor cell lines (GI₅₀ 1.38-1.45 μM) and was more potent than paclitaxel against the drug-resistant KBvin cell line. Compound 5a also inhibited LPS-induced NF-κB activation in RAW264.7 cells with an IC₅₀ value of 0.52 μM, prevented IκB-α degradation and p65 nuclear translocation, and suppressed LPS-induced NO production in a dose-dependent manner. The antitumor data in cellular assays indicated that relative positions and types of substituents on the dibenzocyclooctatetraene or acyclic biphenyl as well as torsional angles between the two phenyls are of primary importance to antitumor activity.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001688 Biological Products Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay. Biologic,Biologic Drug,Biologic Product,Biological,Biological Drug,Biological Medicine,Biological Product,Biologics,Biopharmaceutical,Natural Product,Natural Products,Biologic Drugs,Biologic Medicines,Biologic Pharmaceuticals,Biologic Products,Biological Drugs,Biological Medicines,Biologicals,Biopharmaceuticals,Products, Biological,Drug, Biologic,Drug, Biological,Drugs, Biologic,Drugs, Biological,Medicine, Biological,Medicines, Biologic,Medicines, Biological,Pharmaceuticals, Biologic,Product, Biologic,Product, Biological,Product, Natural
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D016588 Anticarcinogenic Agents Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. Anti-Carcinogenic Agents,Anti-Carcinogenic Drugs,Anti-Carcinogenic Effect,Anti-Carcinogenic Effects,Anticarcinogenic Drugs,Anticarcinogenic Effect,Anticarcinogenic Effects,Anticarcinogens,Agents, Anti-Carcinogenic,Agents, Anticarcinogenic,Anti Carcinogenic Agents,Anti Carcinogenic Drugs,Anti Carcinogenic Effect,Anti Carcinogenic Effects,Drugs, Anti-Carcinogenic,Drugs, Anticarcinogenic,Effect, Anti-Carcinogenic,Effect, Anticarcinogenic,Effects, Anti-Carcinogenic,Effects, Anticarcinogenic

Related Publications

Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
September 2018, Bioorganic chemistry,
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
December 2013, Bioorganic & medicinal chemistry letters,
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
June 2022, Molecules (Basel, Switzerland),
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
April 2021, European journal of medicinal chemistry,
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
January 2017, Anti-cancer agents in medicinal chemistry,
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
March 2016, European journal of medicinal chemistry,
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
December 2021, European journal of medicinal chemistry,
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
October 2018, Bioorganic & medicinal chemistry,
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
July 2017, Molecules (Basel, Switzerland),
Fang-Lin Yu, and Xiao-Yang He, and Chunping Gu, and Emika Ohkoshi, and Li-Ting Wang, and Sheng-Biao Wang, and Chin-Yu Lai, and Le Yu, and Susan L Morris-Natschke, and Kuo-Hsiung Lee, and Shuwen Liu, and Lan Xie
July 2014, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!